Three newly synthesized triphenyltin(IV) compounds, Ph₃SnL1 (L1⁻ = 3-(4-methyl-2-oxoquinolin-1(2H)-yl)propanoato), Ph₃SnL2 (L2⁻ = 2-(4-methyl-2-oxoquinolin-1(2H)-yl)ethanoato), and Ph₃SnL3 (L3⁻ = 2-(4-hydroxy-2-oxoquinolin-1(2H)-yl)ethanoato), were characterized by elemental microanalysis, FT-IR spectroscopy and multinuclear (¹H, ¹³C and ¹¹⁹Sn) NMR spectroscopy. A single X-ray diffraction study indicates that compounds Ph₃SnL1 and Ph₃SnL2 exhibit a 1D zig-zag chain polymeric structure, which in the case of Ph₃SnL2 is additionally stabilized by π-interactions. In addition, the synthesized compounds were further examined using density functional theory and natural bond orbital analysis. The compounds have been evaluated for their in vitro anticancer activity against three human cell lines: MCF-7 (breast adenocarcinoma), A375 (melanoma), HCT116 (colorectal carcinoma), and three murine cell lines: 4T1 (breast carcinoma), B16 (melanoma), CT26 (colon carcinoma) using MTT and CV assays. The IC₅₀ values fall in the nanomolar range, indicating that these compounds possess better anticancer activity than cisplatin. The study of the effect of the newly developed drug Ph₃SnL1 showed its plasticity in achieving an antitumor effect in vitro, which depends on the specificity of the phenotype and the redox status of the malignant cell line and ranges from the initiation of apoptotic cell death to the induction of differentiation to a more mature cell form. In the syngeneic model of murine melanoma, Ph₃SnL1 showed the potential to reduce the tumor volume similar to cisplatin, but in a well-tolerated form and with low systemic toxicity, representing a significant advantage over the conventional drug.

中文翻译：

---

具有羧基 N-功能化 2-喹诺酮类化合物的新型三苯基锡 (IV) 化合物作为有前景的潜在抗癌候选药物：体外和体内评估

三种新合成的三苯基锡( IV )化合物，Ph ₃ SnL1 ( L1 ⁻ = 3-(4-methyl-2-oxoquinolin-1(2 H )-yl)propanoato), Ph ₃ SnL2 ( L2 ⁻ = 2-(4-甲基-2-氧代喹啉-1(2 H )-基)乙酰基)和Ph ₃ SnL3 ( L3 ⁻ = 2-(4-羟基-2-氧代喹啉-1(2 H )-基)乙酰基)，其特征在于元素微量分析、FT-IR 光谱和多核（¹ H、¹³ C 和¹¹⁹ Sn）NMR 光谱。一项 X 射线衍射研究表明，化合物Ph ₃ SnL1和Ph ₃ SnL2表现出一维之字形链聚合结构，在Ph ₃ SnL2的情况下，该结构通过 π 相互作用进一步稳定。此外，利用密度泛函理论和自然键轨道分析进一步检验了合成的化合物。已评估这些化合物对三种人类细胞系：MCF-7（乳腺癌）、A375（黑色素瘤）、HCT116（结直肠癌）和三种鼠细胞系：4T1（乳腺癌）、B16（乳腺癌）的体外抗癌活性。使用 MTT 和 CV 检测来检测黑色素瘤）、CT26（结肠癌）。 IC ₅₀值落在纳摩尔范围内，表明这些化合物比顺铂具有更好的抗癌活性。新开发的药物Ph ₃ SnL1的作用研究表明，其在体外实现抗肿瘤作用的可塑性取决于表型的特异性和恶性细胞系的氧化还原状态，范围从细胞凋亡的起始开始。诱导分化为更成熟的细胞形式。在小鼠黑色素瘤的同系模型中，Ph ₃ SnL1显示出与顺铂类似的减少肿瘤体积的潜力，但其耐受性良好且全身毒性低，与传统药物相比具有显着优势。